Success Metrics

Clinical Success Rate

100.0%

Based on 6 completed trials

Completion Rate

100%(6/6)

Active Trials

0(0%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_1

100%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution6 total trials

Phase 1Safety & dosage

6(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

100.0%

6 of 6 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(6)

Detailed Status

Completed6

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 1

Trials by Phase

Phase 16 (100.0%)

Trials by Status

completed6100%

Recent Activity

0 active trials

Showing 5 of 6

completedphase_1

BMS-214662 in Treating Patients With Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myeloid Leukemia

NCT00006213

completedphase_1

Paclitaxel and BMS-214662 in Treating Patients With Advanced Solid Tumors

NCT00006018

View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials

NCT00006242Phase 1

BMS-214662 in Treating Patients With Advanced Solid Tumors

Completed

NCT00022529Phase 1

BMS-214662 Plus Trastuzumab in Treating Patients With Advanced Solid Tumors

Completed

NCT00005973Phase 1

BMS-214662 in Treating Patients With Solid Tumors

Completed

NCT00006213Phase 1

BMS-214662 in Treating Patients With Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myeloid Leukemia

Completed

NCT00006018Phase 1

Paclitaxel and BMS-214662 in Treating Patients With Advanced Solid Tumors

Completed

NCT00004877Phase 1

BMS-214662 in Treating Patients With Advanced Solid Tumors

Completed

All 6 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 6